Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes

被引：78

作者：

Sjostrom, C. David ^{[1
]}

Johansson, Peter ^{[1
]}

Ptaszynska, Agata ^{[2
]}

List, James ^{[2
]}

Johnsson, Eva ^{[1
]}

机构：

[1] AstraZeneca, SE-43183 Molndal, Sweden

[2] Bristol Myers Squibb Co, Princeton, NJ USA

来源：

DIABETES & VASCULAR DISEASE RESEARCH | 2015年 / 12卷 / 05期

关键词：

Dapagliflozin; sodium-glucose co-transporter 2 inhibitor; hypertension; blood pressure; type; 2; diabetes; ANGIOTENSIN-ALDOSTERONE SYSTEM; DOUBLE-BLIND; WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; ADD-ON; MELLITUS; INSULIN; GUIDELINES; MANAGEMENT;

D O I：

10.1177/1479164115585298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (<140mmHg) and hypertensive (>= 140mmHg) patients with type 2 diabetes mellitus. Data were pooled from 13 placebo-controlled studies. Patients received dapagliflozin 10mg/day (n=2360) or placebo (n=2295) for up to 24weeks. Dapagliflozin was associated with placebo-subtracted changes from baseline in systolic and diastolic blood pressures of -3.6 and -1.2mmHg, respectively, in hypertensive patients and -2.6 and -1.2mmHg, respectively, in non-hypertensive patients. At 24weeks, a similar proportion of patients experienced measured orthostatic reactions with dapagliflozin versus placebo in hypertensive (6.1% and 6.6%, respectively) and non-hypertensive (4.0% and 4.2%) patients. No clinically relevant difference was observed between dapagliflozin and placebo in heart rate. In conclusion, dapagliflozin 10mg induces a modest reduction in blood pressure compared with placebo in patients with diabetes with a low risk of orthostatic reactions, regardless of baseline blood pressure.

引用

页码：352 / 358

页数：7

共 23 条

[1] Standards of Medical Care in Diabetes-2014 [J].